Jaguar Health, Inc. (JAGX) Form 8-K — Aug 19, 2026
Jaguar Health reported Q2 2026 total net revenue of $1.2 million, down 59% from $3.0 million in Q2 2025, reflecting the January 2026 licensing of Mytesi and Canalevia-CA1 U.S. rights to Future Pak, which is now the exclusive U.S. marketer. Net loss attributable to common stockholders widened 22% to $12.7 million ($15.68 per share) from $10.4 million, driven by non-operating items including a $3.5 million loss on extinguishment of debt and a swing to $161,000 of interest expense, while non-GAAP recurring EBITDA loss was $8.4 million.
Key figures
- Revenue
- 1225000
- Revenue Yoy
- -59%
- Rd expense
- 3300000
- Holdback payment
- 2000000
- Product revenue net
- 1182000
- License grant revenue
- 43000
- Future pak upfront payment
- 16000000
- Product revenue yoy change
- -60%
- Loss on debt extinguishment
- 3504000
- Federal grant revenue cid dogs
- 25520
- Sales marketing expense q2 2026
- 5000
- Deferred revenue european partner
- 468000
- Mvid parenteral support reduction
- up to 48%
- Buyback option termination payment
- 3000000
Price after filing
Close on the filing date to close N calendar days later (from $0.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.